RT Journal Article
SR Electronic
T1 Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.01.20079376
DO 10.1101/2020.05.01.20079376
A1 D. De Smet
A1 K. De Smet
A1 P. Herroelen
A1 S. Gryspeerdt
A1 G.A. Martens
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.01.20079376.abstract
AB Context Through its immunological functions, vitamin D attenuates inflammatory responses to respiratory viruses. Vitamin D deficiency might be a highly prevalent risk factor for severe SARS-CoV-2 infections.Objective To investigate the level of vitamin D deficiency in West Flanders, Belgium and its correlation to severity of COVID-19 as staged by CTDesign Retrospective observational studySetting. Central network hospitalParticipants 186 SARS-CoV-2-infected patients hospitalized from March 1, 2020 to April 7, 2020Main outcome measure Analysis of 25(OH)D in COVID-19 patients versus season/age/sex-matched diseased controlsResults The rate of vitamin D deficiency (25(OH)D<20 ng/mL) in West Flanders varies with age, sex and season but is overall very high (39.9%) based on analysis of 16274 control samples. We measured 25(OH)D levels in 186 COVID-19 patients (109 males (median age 68 years, IQR 53-79) and 77 females (median age 71 years, IQR 65-74)) and 2717 age/season-matched controls (999 males (median age 69 years, IQR 53-81) and 1718 females (median age 68 years, IQR 43-83)). COVID-19 patients showed lower median 25(OH)D (18.6 ng/mL, IQR 12.6-25.3, versus 21.5 ng/mL, IQR 13.9-30.8; P=0.0016) and higher vitamin D deficiency rates (58.6% versus 45.2%, P=0.0005). Surprisingly, this difference was restricted to male COVID-19 patients who had markedly higher deficiency rates than male controls (67.0% versus 49.2%, P=0.0006) that increased with advancing radiological stage and were not confounded vitamin D-impacted comorbidities.Conclusions vitamin D deficiency is a prevalent risk factor for severe COVID-19. Vitamin D supplementation might be an inexpensive and safe mitigation for the SARS-CoV-2 pandemic.SUMMARY BOXWhat is already known on this topicWhat is already known on this topic Vitamin D deficiency increases the incidence and severity of respiratory viral infections by exacerbation of pro-inflammatory immune responses. Lung damage in COVID-19 involves excessive inflammation and cytokine release. With more than 1 billion people worldwide affected by vitamin D deficiency the world might now face a convergence of two pandemics. Data are emerging that variations in vitamin D deficiency rates across ethnic and demographic subgroups are correlated to severity of SARS-CoV-2 infections.What this study addsWhat this study adds Our data reveal that more than 40% of the adult population in a wealthy European country is vitamin D deficient. We show that vitamin D deficiency is correlated with the risk for hospitalization for COVID-19 pneumonia and predisposes to more advanced radiological disease stages. Specifically, men were at risk. This correlation was not confounded by vitamin D-impacted morbidities such as coronary artery disease, diabetes and chronic lung disease. Our findings support a causal relation between vitamin D deficiency and severe COVID-19 and call for vitamin D supplementation as safe, widely available and inexpensive mitigation strategy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trial Number IRB B1172020000009Funding StatementThis work was not funded by external or commercial sources. The costs for this study were covered by the authors and AZ Delta General Hospital.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data required for independent reproduction of our study are included in the manuscript and online supplementary files. The raw data are freely available on email request.